Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Sandra Eder, Jonathan Canaani, Eric Beohou, Myriam Labopin, Jaime Sanz, William Arcese, Reuven Or, Juergen Finke, Agostino Cortelezzi, Dietrich Beelen, Jakob Passweg, Gerard Socié, Gunhan Gurman, Mahmoud Aljurf, Matthias Stelljes, Sebastian Giebel, Mohamad Mohty, Arnon Nagler

Research output: Contribution to journalArticle

Abstract

The optimal conditioning regimen to employ before hematopoietic stem cell transplantation in acute lymphoblastic leukemia (ALL) is still undecided, and while cyclophosphamide/total body irradiation (Cy/TBI) is the most commonly used myeloablative regimen, there are concerns regarding long-term toxicity for patients conditioned with this regimen. Thiotepa-based conditioning is an emerging radiation-free regimen with recent publications indicative of comparable clinical outcomes to TBI-based conditioning. In this analysis of the acute leukemia working party of the EBMT, we performed a retrospective matched-pair analysis, evaluating the outcome of adult patients with ALL who received thiotepa-based conditioning (n = 180) with those receiving Cy/TBI conditioning (n = 540). The 2-year leukemia-free survival and overall survival (OS) rates of both conditioning regimens were comparable, 33% for thiotepa [95% confidence interval (CI): 26.4-42.8] versus 39% for Cy/TBI (95% CI: 34.8-44.5] (P =.33) and 46.5% [95% CI: 38.6-56.1] versus 48.8% [95% CI: 44.2-54] (P =.9), respectively. There was no significant difference between the two regimens in the incidence of either acute graft versus host disease (GVHD) or chronic GVHD. Multivariate analysis demonstrated increased relapse incidence for thiotepa conditioning compared to Cy/TBI (HR = 1.78, 95% CI, 1.07-2.95; P =.03) which did not affect OS. Our results indicate that thiotepa-based conditioning may not be inferior to Cy/TBI for adult patients with ALL.

Original languageEnglish
Pages (from-to)997-1003
Number of pages7
JournalAmerican Journal of Hematology
Volume92
Issue number10
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

Thiotepa
Matched-Pair Analysis
Whole-Body Irradiation
Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cyclophosphamide
Leukemia
Transplantation
Bone Marrow
Confidence Intervals
Graft vs Host Disease
Survival
Hematopoietic Stem Cell Transplantation
Incidence
Multivariate Analysis
Survival Rate
Radiation
Recurrence

ASJC Scopus subject areas

  • Hematology

Cite this

Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia : A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. / Eder, Sandra; Canaani, Jonathan; Beohou, Eric; Labopin, Myriam; Sanz, Jaime; Arcese, William; Or, Reuven; Finke, Juergen; Cortelezzi, Agostino; Beelen, Dietrich; Passweg, Jakob; Socié, Gerard; Gurman, Gunhan; Aljurf, Mahmoud; Stelljes, Matthias; Giebel, Sebastian; Mohty, Mohamad; Nagler, Arnon.

In: American Journal of Hematology, Vol. 92, No. 10, 01.10.2017, p. 997-1003.

Research output: Contribution to journalArticle

Eder, Sandra ; Canaani, Jonathan ; Beohou, Eric ; Labopin, Myriam ; Sanz, Jaime ; Arcese, William ; Or, Reuven ; Finke, Juergen ; Cortelezzi, Agostino ; Beelen, Dietrich ; Passweg, Jakob ; Socié, Gerard ; Gurman, Gunhan ; Aljurf, Mahmoud ; Stelljes, Matthias ; Giebel, Sebastian ; Mohty, Mohamad ; Nagler, Arnon. / Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia : A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. In: American Journal of Hematology. 2017 ; Vol. 92, No. 10. pp. 997-1003.
@article{dcaf369860a64180a3855b1762d17019,
title = "Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation",
abstract = "The optimal conditioning regimen to employ before hematopoietic stem cell transplantation in acute lymphoblastic leukemia (ALL) is still undecided, and while cyclophosphamide/total body irradiation (Cy/TBI) is the most commonly used myeloablative regimen, there are concerns regarding long-term toxicity for patients conditioned with this regimen. Thiotepa-based conditioning is an emerging radiation-free regimen with recent publications indicative of comparable clinical outcomes to TBI-based conditioning. In this analysis of the acute leukemia working party of the EBMT, we performed a retrospective matched-pair analysis, evaluating the outcome of adult patients with ALL who received thiotepa-based conditioning (n = 180) with those receiving Cy/TBI conditioning (n = 540). The 2-year leukemia-free survival and overall survival (OS) rates of both conditioning regimens were comparable, 33{\%} for thiotepa [95{\%} confidence interval (CI): 26.4-42.8] versus 39{\%} for Cy/TBI (95{\%} CI: 34.8-44.5] (P =.33) and 46.5{\%} [95{\%} CI: 38.6-56.1] versus 48.8{\%} [95{\%} CI: 44.2-54] (P =.9), respectively. There was no significant difference between the two regimens in the incidence of either acute graft versus host disease (GVHD) or chronic GVHD. Multivariate analysis demonstrated increased relapse incidence for thiotepa conditioning compared to Cy/TBI (HR = 1.78, 95{\%} CI, 1.07-2.95; P =.03) which did not affect OS. Our results indicate that thiotepa-based conditioning may not be inferior to Cy/TBI for adult patients with ALL.",
author = "Sandra Eder and Jonathan Canaani and Eric Beohou and Myriam Labopin and Jaime Sanz and William Arcese and Reuven Or and Juergen Finke and Agostino Cortelezzi and Dietrich Beelen and Jakob Passweg and Gerard Soci{\'e} and Gunhan Gurman and Mahmoud Aljurf and Matthias Stelljes and Sebastian Giebel and Mohamad Mohty and Arnon Nagler",
year = "2017",
month = "10",
day = "1",
doi = "10.1002/ajh.24823",
language = "English",
volume = "92",
pages = "997--1003",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia

T2 - A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

AU - Eder, Sandra

AU - Canaani, Jonathan

AU - Beohou, Eric

AU - Labopin, Myriam

AU - Sanz, Jaime

AU - Arcese, William

AU - Or, Reuven

AU - Finke, Juergen

AU - Cortelezzi, Agostino

AU - Beelen, Dietrich

AU - Passweg, Jakob

AU - Socié, Gerard

AU - Gurman, Gunhan

AU - Aljurf, Mahmoud

AU - Stelljes, Matthias

AU - Giebel, Sebastian

AU - Mohty, Mohamad

AU - Nagler, Arnon

PY - 2017/10/1

Y1 - 2017/10/1

N2 - The optimal conditioning regimen to employ before hematopoietic stem cell transplantation in acute lymphoblastic leukemia (ALL) is still undecided, and while cyclophosphamide/total body irradiation (Cy/TBI) is the most commonly used myeloablative regimen, there are concerns regarding long-term toxicity for patients conditioned with this regimen. Thiotepa-based conditioning is an emerging radiation-free regimen with recent publications indicative of comparable clinical outcomes to TBI-based conditioning. In this analysis of the acute leukemia working party of the EBMT, we performed a retrospective matched-pair analysis, evaluating the outcome of adult patients with ALL who received thiotepa-based conditioning (n = 180) with those receiving Cy/TBI conditioning (n = 540). The 2-year leukemia-free survival and overall survival (OS) rates of both conditioning regimens were comparable, 33% for thiotepa [95% confidence interval (CI): 26.4-42.8] versus 39% for Cy/TBI (95% CI: 34.8-44.5] (P =.33) and 46.5% [95% CI: 38.6-56.1] versus 48.8% [95% CI: 44.2-54] (P =.9), respectively. There was no significant difference between the two regimens in the incidence of either acute graft versus host disease (GVHD) or chronic GVHD. Multivariate analysis demonstrated increased relapse incidence for thiotepa conditioning compared to Cy/TBI (HR = 1.78, 95% CI, 1.07-2.95; P =.03) which did not affect OS. Our results indicate that thiotepa-based conditioning may not be inferior to Cy/TBI for adult patients with ALL.

AB - The optimal conditioning regimen to employ before hematopoietic stem cell transplantation in acute lymphoblastic leukemia (ALL) is still undecided, and while cyclophosphamide/total body irradiation (Cy/TBI) is the most commonly used myeloablative regimen, there are concerns regarding long-term toxicity for patients conditioned with this regimen. Thiotepa-based conditioning is an emerging radiation-free regimen with recent publications indicative of comparable clinical outcomes to TBI-based conditioning. In this analysis of the acute leukemia working party of the EBMT, we performed a retrospective matched-pair analysis, evaluating the outcome of adult patients with ALL who received thiotepa-based conditioning (n = 180) with those receiving Cy/TBI conditioning (n = 540). The 2-year leukemia-free survival and overall survival (OS) rates of both conditioning regimens were comparable, 33% for thiotepa [95% confidence interval (CI): 26.4-42.8] versus 39% for Cy/TBI (95% CI: 34.8-44.5] (P =.33) and 46.5% [95% CI: 38.6-56.1] versus 48.8% [95% CI: 44.2-54] (P =.9), respectively. There was no significant difference between the two regimens in the incidence of either acute graft versus host disease (GVHD) or chronic GVHD. Multivariate analysis demonstrated increased relapse incidence for thiotepa conditioning compared to Cy/TBI (HR = 1.78, 95% CI, 1.07-2.95; P =.03) which did not affect OS. Our results indicate that thiotepa-based conditioning may not be inferior to Cy/TBI for adult patients with ALL.

UR - http://www.scopus.com/inward/record.url?scp=85025065390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025065390&partnerID=8YFLogxK

U2 - 10.1002/ajh.24823

DO - 10.1002/ajh.24823

M3 - Article

AN - SCOPUS:85025065390

VL - 92

SP - 997

EP - 1003

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 10

ER -